Delayed escalation in advanced prostate cancer compromises outcomes.
Explore the clinical rationale behind moving directly to doublet or triplet combinations to protect long-term patient survival.
Watch the clip here ➡️ https://t.co/BAnaZ16wxO
#Oncology#MedEd#CME
Monotherapy is rapidly being relegated to the past.
Learn why early combination protocols are non-negotiable to delay progression to castration resistance and maximize patient survival.
Catch up on the latest data ➡️ https://t.co/BAnaZ16wxO
#Oncology#MedEd#CME
Early treatment intensification is a game-changer in mHSPC.
Watch as experts explain why missing the early treatment window means patients can't make up the lost survival benefit later.
Watch the full episode ➡️ https://t.co/BAnaZ16wxO
#Oncology#MedEd#CME
Starting in 1 HOUR ➡️ https://t.co/wVu86Pv1fb
mHSPC care is evolving rapidly. Join our live expert exchange with Dr. Shore, Dr. McKay, and Dr. Caulfield to explore the latest clinical data on treatment intensification and combination management.
#Oncology#Urology#CME
LIVE TOMORROW: A deep dive into doublet and triplet combinations for mHSPC. ➡️ https://t.co/wVu86Pv1fb
Equip your interprofessional care team with practical tools to manage treatment intensification strategies and elevate patient care. See you there!
🗓️ May 27th
⏰ 12:30pm EST
Intensifying treatment beyond ADT is critical in mHSPC.
Join our expert panel to dive into combination therapies, manage drug interactions, and get actionable insights for your practice.
🗓️ May 27th
⏰ 12:30pm EST
🔗 https://t.co/wVu86Pv1fb
SAVE THE DATE 🗓️
mHSPC treatment landscape is shifting. Join Dr. Neal Shore, Dr. Rana McKay, and Sarah Caulfield, PharmD, BCOP, as they evaluate the latest evidence for emerging doublet and triplet combination strategies.
🗓️ May 27th
⏰ 12:30pm EST
🔗 https://t.co/wVu86Pv1fb